Navigation Links
GlaxoSmithKline Signs Outsourcing Deal With TCS

GlaxoSmithKline (GSK), Britain's largest drug company, // has signed an outsourcing deal with India's Tata Consulting Services to establish a drug development support facility in Mumbai.

A company statement said that under the terms of the deal, TCS will support GSK's global clinical research and development programme by providing outsourced data management and medical trial reporting services.

The arrangement will create nearly 100 new jobs on an existing site and reports say that the deal is understood to be worth more than £ 10 million.

GSK already has sizeable research operations in Mumbai and Bangalore and employs 2,400 people in India, where it controls 5.9 per cent of the pharmaceuticals market, The Times said.

Amber Salzman, senior vice-president of development operations at GSK, said in a statement that the company had picked TCS as a partner because of its strong record in knowledge process outsourcing and operational excellence.

Like many global companies GSK has been seeking to tap into India's pool of high-quality IT and scientific talent and is aiming to trim costs through outsourcing.

GSK is also involved in research collaboration with India's Ranbaxy Laboratories, to jointly develop drugs in areas such as urology, diabetes and asthma. Earlier this year, GSK announced that pre-tax profits rose 16 per cent in 2006 to £ 7.8 billion on the previous year, on turnover of £ 23.2 billion. br>
Source-IANS
SM
'"/>




Page: 1

Related medicine news :

1. GlaxoSmithKline - Changes Lamictal(R) Label Appearance and Packaging
2. GlaxoSmithKline To Cultivate Non-Smoking Environment
3. GlaxoSmithKline to Supply United States with 8 Million flu vaccine, Fluarix
4. FDA Mislead On Asthma Drug By GlaxoSmithKline
5. GlaxoSmithKline Defends Its Products
6. GlaxoSmithKline launches diabetes and cancer drugs
7. Generic Products Compete With GlaxoSmithKline
8. GlaxoSmithKline Agrees To Settle Paxil Claims For $14 million
9. GlaxoSmithKlines Zofran Helps In Treatment Of Dehydration In Children
10. GlaxoSmithKline’s Epilepsy Drug given the Green Signal by FD
11. GlaxoSmithKline’s Tykerb is to Be Started Earlier in Breast Cancer, Study Find
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, ... its strategic partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a ... effective management of complex spine deformity cases, particularly in children. , GSO’s focus ...
(Date:4/24/2017)... Lake City, UT (PRWEB) , ... April 24, 2017 , ... ... their efforts to encourage sustainability, innovate new strategies to reduce waste, and support renewable ... herbal remedy provider. They look to nature to find solutions for health issues, and ...
(Date:4/24/2017)... , ... April 24, 2017 , ... The California Dental ... in charitable dental services to 1,961 people during the April 22-23 event at the ... charge to Californians who experience barriers to care, CDA Cares educates the public and ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... seeking public support to bring their novel lifesaving device for the everyday use ... with medical-grade sensors, specially designed to read a child’s vital signs, and detect ...
(Date:4/24/2017)... CA (PRWEB) , ... April 24, 2017 , ... ... brain tumors are expected to be diagnosed globally; approximately 25,000 of them will ... are anticipating greater use of this type of healthcare model in the diagnosis ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
Breaking Medicine Technology: